Effectiveness of Platelet Function Analyzer-100 for Laboratory Detection of Anti-Platelet Drug-Induced Platelet Dysfunction

키워드

참고문헌 (40)

1. Mammen EF, "PFA-100 system : a new method for assessment of platelet dysfunction", Semin Thromb Hemost, 24, pp.195~202 (1998)
2. Fintel DJ, "Oral antiplatelet therapy for atherothrombotic disease : overview of current and emerging treatment options", Vasc Health Risk Manag, 8, pp.77~89 (2012)
3. Stegnar M, "Platelet function tests and resistance to antiplatelet therapy", Srp Arh Celok Lek, 138, pp.59~63 (2010)
4. Lordkipanidzé M, "Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients", Eur Heart J, 29, pp.2877~2885 (2008)
5. Cattaneo M, "Resistance to antiplatelet drugs : molecular mechanisms and laboratory detection", J Thromb Haemost, 5, pp.230~237 (2007)
6. Agarwal S, "Quantifying the effect of antiplatelet therapy : a comparison of the Platelet Function Analyzer(PFA-100®)and modified thromboelastography(mTEG®)with light transmission platelet aggregometry", Anesthesiology, 105, pp.676~683 (2006)
7. Bartels A, "Failure of the platelet function assay(PFA)-100 to detect antiplatelet agents", Surgery, 158, pp.1012~1018 (2015)[DOI]
8. Baigent C, "Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease : a reappraisal", Arthritis Rheum, 48, pp.12~20 (2003)
9. Bozimowski G, "A review of nonsteroidal anti-inflammatory drugs", AANA J, 83, pp.425~433 (2015)
10. Goldenberg NA, "Brief communication : duration of platelet dysfunction after a 7-day course of ibuprofen", Ann Intern Med, 142, pp.506~509 (2005)
11. van Kraaij DJ, "A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers", Br J Clin Pharmacol, 53, pp.644~647 (2002)
12. Kearney PM, "Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials", BMJ, 332, pp.1302~1308 (2006)
13. 김정아, "Influence of Blood Lipids on Global Coagulation Test Results", Annals of Laboratory Medicine, 35(1), pp.15~21 (2015), 대한진단검사의학회
14. Catena C, "Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance", Am J Med, 109, pp.556~561 (2000)
15. Jakl M, "High on-treatment platelet reactivity : risk factors and 5-year outcomes in patients with acute myocardial infarction", Anatol J Cardiol, 17, pp.113~118 (2017)
16. Park KW, "Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans", Cardiovasc Ther, 30, pp.5~11 (2012)
17. Maree AO, "Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease", J Am Coll Cardiol, 46, pp.1258~1263 (2005)
18. Kundu SK, "Description of an in vitro platelet function analyzer--PFA-100", Semin Thromb Hemost, 21(S2), pp.106~112 (1995)
19. Harrison P, "Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis", Blood Coagul Fibrinolysis, 10, pp.25~31 (1999)
20. Warner TD, "Anti-platelet therapy : cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy", Br J Clin Pharmacol, 72, pp.619~633 (2011)
21. 조영욱, "한국인 성인에서 Platelet Function Analyzer-100 폐색시간의분석 전 변수 확인 및 참고범위 설정", Annals of Laboratory Medicine, 27(5), pp.318~323 (2007), 대한진단검사의학회
22. Paniccia R, "Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients", J Thromb Haemost, 5, pp.1839~1847 (2007)
23. Patrono C, "Drug insight : aspirin resistance--fact or fashion", Nat Clin Pract Cardiovasc Med, 4, pp.42~50 (2007)
24. Harrison P, "Screening for aspirin responsiveness after transient ischemic attack and stroke : comparison of 2 point-of-care platelet function tests with optical aggregometry", Stroke, 36, pp.1001~1005 (2005)
25. Cattaneo M, "Aspirin and clopidogrel : efficacy, safety, and the issue of drug resistance", Arterioscler Thromb Vasc Biol, 24, pp.1980~1987 (2004)
26. Peters BJ, "CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel", Pharmacogenomics, 12, pp.141~144 (2011)
27. Xie HG, "Individual variability in the disposition of and response to clopidogrel : pharmacogenomics and beyond", Pharm Ther, 129, pp.267~289 (2011)
28. Bouman HJ, "Paraoxonase-1 is a major determinant of clopidogrel efficacy", Nat Med, 17, pp.110~116 (2011)
29. Arméro S, "Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy", Platelets, 21, pp.503~507 (2010)
30. Wijeyeratne YD, "Anti-platelet therapy : ADP receptor antagonists", Br J Clin Pharmacol, 72, pp.647~657 (2011)
31. Blaicher AM, "Effect of non-selective, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors on the PFA-100 closure time", Anaesthesia, 59, pp.1100~1103 (2004)
32. Favaloro EJ, "Clinical utility of the PFA-100", Semin Thromb Hemost, 34, pp.709~733 (2008)
33. Angchaisuksiri P, "Cancer-associated thrombosis in Asia", Thromb J, 14(S1), pp.26~ (2016)
34. Mahé I, "Factors influencing adherence to clinical guidelines in the management of cancer-associated thrombosis", J Thromb Haemost, 14, pp.2107~2113 (2016)
35. Caine GJ, "The hypercoagulable state of malignancy : pathogenesis and current debate", Neoplasia, 4, pp.465~473 (2002)
36. Falanga A, "Coagulation and cancer : biological and clinical aspects", J Thromb Haemost, 11, pp.223~233 (2013)
37. Nierodzik ML, "Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo", Thromb Haemost, 74, pp.282~290 (1995)
38. Lima LG, "Activation of blood coagulation in cancer : implications for tumour progression", Biosci Rep, 33, pp.e00064~ (2013)
39. Falanga A, "Procoagulant mechanisms in tumour cells", Best Pract Res Clin Haematol, 22, pp.49~60 (2009)
40. 이명숙, "가능성 있는 폰빌레브란트병의 유병률에 대한 연구", Clinical Pediatric Hematology-Oncology, 21(1), pp.16~22 (2014), 대한소아혈액종양학회

관련 논문AI추천